← Back to Search

Genetic Testing

Screening Method for Lynch Syndrome in Endometrial and Ovarian Cancer (LS2 Trial)

N/A

Waitlist Available

Led By Sarah Ferguson, MD

Research Sponsored by University Health Network, Toronto

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients must be 18-70 years old

Patients must have endometrial cancer (all grades, stages and histologic subtypes except stromal sarcoma, carcinosarcoma)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up short-term assessment at 1 year after diagnosis, long-term assessment for up to 10 years after diagnosis

Awards & highlights

LS2 Trial Summary

This trial will test a new way of identifying women with Lynch Syndrome, a hereditary disease that can lead to cancer. If successful, it could improve screening and surgery options for women at risk.

Who is the study for?

This trial is for women aged 18-70 in Canada with endometrial cancer (excluding certain types) diagnosed within the last 6 months. Participants must have tumor tissue available and be able to consent. Their adult first-degree relatives can join if they give consent and live in Canada.Check my eligibility

What is being tested?

The study tests an enhanced screening strategy for Lynch Syndrome among women with specific cancers, offering genetic counseling and testing. It also evaluates adherence to recommended guidelines over ten years after a Lynch Syndrome diagnosis.See study design

What are the potential side effects?

Since this trial involves questionnaires and educational materials rather than medical treatments, traditional side effects are not expected. However, participants may experience stress or anxiety related to learning about their genetic risks.

LS2 Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 18 and 70 years old.

Select...

I have endometrial cancer, but it's not stromal sarcoma or carcinosarcoma.

Select...

My cancer tissue is available for a specific protein test.

LS2 Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ short-term assessment at 1 year after diagnosis, long-term assessment for up to 10 years after diagnosis

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~short-term assessment at 1 year after diagnosis, long-term assessment for up to 10 years after diagnosis

This trial's timeline: 3 weeks for screening, Varies for treatment, and short-term assessment at 1 year after diagnosis, long-term assessment for up to 10 years after diagnosis for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Adherence to screening guidelines (colonoscopy and gynecologic risk-reducing surgery) in participants found to have Lynch Syndrome

Cost-effectiveness of universal enhanced screening strategy to identify women with Lynch Syndrome and their family members via cascade testing

Secondary outcome measures

Discovery of novel genetic mutations and molecular events in unexplained MMR loss (Lynch-like Syndrome)

Incidence of Lynch Syndrome in an unselected group of women with endometrial and non-serous ovarian cancer

LS2 Trial Design

1Treatment groups

Experimental Treatment

Group I: Endometrial and Ovarian Cancer ParticipantsExperimental Treatment1 Intervention

All study subjects will be offered the same options for screening and follow-up.

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

Sunnybrook Health Sciences CentreOTHER

656 Previous Clinical Trials

1,549,736 Total Patients Enrolled

University of TorontoOTHER

689 Previous Clinical Trials

1,017,757 Total Patients Enrolled

Mount Sinai Hospital, CanadaOTHER

196 Previous Clinical Trials

66,722 Total Patients Enrolled

Media Library

Enhanced Screening Strategy (Genetic Testing) Clinical Trial Eligibility Overview. Trial Name: NCT02494791 — N/A

Lynch Syndrome Research Study Groups: Endometrial and Ovarian Cancer Participants

Lynch Syndrome Clinical Trial 2023: Enhanced Screening Strategy Highlights & Side Effects. Trial Name: NCT02494791 — N/A

Enhanced Screening Strategy (Genetic Testing) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02494791 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment still open for this research project?

"This trial, which was initially posted on July 1st 2015 and last updated 16th May 2022, is no longer accepting patients. Nevertheless, there are 5139 other medical studies currently seeking participants."

Answered by AI